Omeros, Patobios Ltd. deal

Omeros exercised its 2008 option and acquired IP related to a GPCR assay technology from Patobios for C$7.8 million ($7.7 million) in cash and C$3 million ($2.9 million) in stock. Omeros used a portion of the $20 million it received in funding from Vulcan Capital earlier this year to exercise the option. Omeros does not have any additional financial obligations to Patobios related to the IP (see BioCentury, Nov. 1). ...